EirGenix Inc. (TPEX: 6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
73.10
-1.40 (-1.88%)
Dec 19, 2024, 1:30 PM CST
-27.98%
Market Cap 21.96B
Revenue (ttm) 1.17B
Net Income (ttm) -986.69M
Shares Out 306.25M
EPS (ttm) -3.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 897,255
Open 73.50
Previous Close 74.50
Day's Range 73.00 - 74.30
52-Week Range 66.90 - 103.00
Beta 0.61
Analysts n/a
Price Target n/a
Earnings Date Mar 21, 2025

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2023, EirGenix's revenue was 1.02 billion, a decrease of -30.95% compared to the previous year's 1.48 billion. Losses were -915.21 million, 692.1% more than in 2022.

Financial Statements

News

There is no news available yet.